Cancer Treatment Localization: Boston Oncology Arabia & SPIMACO Partner in Saudi Arabia

Cancer Treatment Localization: Boston Oncology Arabia & SPIMACO Partner in Saudi Arabia In a groundbreaking move to enhance cancer care in the Middle East, Boston Oncology Arabia and SPIMACO have formalized their collaboration through a Memorandum of Understanding (MoU) aimed…

Read MoreCancer Treatment Localization: Boston Oncology Arabia & SPIMACO Partner in Saudi Arabia

Partnering for Bispecific Antibodies and ADCs: Biocytogen and Acepodia

Partnering for Bispecific Antibodies and ADCs: Biocytogen and Acepodia Biocytogen (HKEX: 02315) and Acepodia (6976:TT) have announced a strategic partnership aimed at jointly evaluating a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This collaboration marks a significant step forward in their…

Read MorePartnering for Bispecific Antibodies and ADCs: Biocytogen and Acepodia

Detection of Hyperkalemia Powered by AI Receives FDA Breakthrough Designation

Detection of Hyperkalemia Powered by AI Receives FDA Breakthrough Designation AccurKardia, a leading innovator in ECG-based diagnostic technology, has announced that its AI-powered AK+ Guard™ hyperkalemia detection software has received Breakthrough Device Designation from the U.S. Food and Drug Administration…

Read MoreDetection of Hyperkalemia Powered by AI Receives FDA Breakthrough Designation

Stoke Therapeutics Announces Phase 3 Study Plans for Zorevunersen in Dravet Syndrome

Stoke Therapeutics Announces Phase 3 Study Plans for Zorevunersen in Dravet Syndrome Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on RNA medicine to restore protein expression, announced today that it has finalized its Phase 3 EMPEROR study design…

Read MoreStoke Therapeutics Announces Phase 3 Study Plans for Zorevunersen in Dravet Syndrome